China News Service, February 8th. According to the official WeChat public account of the National Medical Insurance Bureau on the 8th, the person in charge of the Medical Management Department of the National Medical Insurance Bureau answered reporters' questions about the medical insurance support policy for the newly listed domestically produced new crown treatment drugs. The new crown treatment drugs have all been included in the scope of medical insurance payment.
Among them, the traditional Chinese medicine "Three Drugs and Three Prescriptions" and Azivudine Tablets have been officially included in the medical insurance drug list, and deuterium remidevir hydrobromide tablets, cenotevir tablets/ritonavir tablet combination packaging and other drugs are temporarily included in the medical insurance payment range.
On January 29, 2023, the State Food and Drug Administration conditionally approved the new coronavirus infection treatment drug Deuterium Remidevir Tablets (trade name: Mindev), Hainan Xiansheng Pharmaceutical Co., Ltd. announced the launch of the combined packaging of the new coronavirus infection treatment drug cenotevir tablets/ritonavir tablets (trade name: cenotevir).
The person in charge of the Medical Management Department of the National Medical Insurance Bureau answered questions from reporters on the current medical insurance payment policy for these two drugs.
According to the person in charge, according to the National Health Commission's "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)", the above two drugs belong to the scope of the tenth edition of the diagnosis and treatment plan.
On January 30, the National Medical Insurance Administration issued a document requiring all provincial medical security departments to optimize the treatment costs of patients with new coronavirus infection in accordance with the "National Medical Insurance Administration, Ministry of Finance, National Health and Health Commission, and National Disease Control and Prevention Bureau's implementation of "Class B and B Management". The Notice on Relevant Policies for Medical Security (Yibaofa [2023] No. 1) requires that two medicines, Remidevir Hydrobromide Tablets and Cenotavir Tablets/Ritonavir Tablets Combination Packaging, be temporarily included in this province The payment scope of the basic medical insurance fund is to be paid until March 31, 2023; at the same time, the relevant provincial medical insurance bureaus are required to perform the duties of the drug price authorities in accordance with the law, and do a good job of accepting and guiding the initial quotation of relevant drugs in accordance with the "Guidelines for the Formation of New Coronary Drug Price Formation (Trial)" work, disclose price composition information, and accept social supervision.